Your browser is no longer supported. Please, upgrade your browser.
NVS Novartis AG weekly Stock Chart
Novartis AG
Index- P/E28.57 EPS (ttm)3.08 Insider Own9.30% Shs Outstand2.51B Perf Week-9.52%
Market Cap220.83B Forward P/E13.94 EPS next Y6.31 Insider Trans0.11% Shs Float2.35B Perf Month-6.31%
Income7.14B PEG3.68 EPS next Q1.37 Inst Own11.40% Short Float0.17% Perf Quarter-2.85%
Sales48.62B P/S4.54 EPS this Y-43.60% Inst Trans5.68% Short Ratio2.21 Perf Half Y-0.55%
Book/sh24.44 P/B3.60 EPS next Y10.20% ROA9.60% Target Price102.67 Perf Year7.78%
Cash/sh4.56 P/C19.29 EPS next 5Y7.77% ROE22.70% 52W Range74.97 - 99.84 Perf YTD-7.12%
Dividend3.04 P/FCF39.43 EPS past 5Y-6.50% ROI8.60% 52W High-12.68% Beta0.64
Dividend %3.46% Quick Ratio0.80 Sales past 5Y-1.90% Gross Margin71.40% 52W Low16.29% ATR1.60
Employees103914 Current Ratio1.00 Sales Q/Q7.10% Oper. Margin18.70% RSI (14)24.61 Volatility2.10% 1.27%
OptionableYes Debt/Eq0.53 EPS Q/Q-6.50% Profit Margin24.10% Rel Volume2.76 Prev Close87.95
ShortableYes LT Debt/Eq0.40 EarningsJan 29 BMO Payout55.60% Avg Volume1.82M Price87.18
Recom1.00 SMA20-8.99% SMA50-8.21% SMA200-3.50% Volume4,565,285 Change-0.88%
Feb-25-20Downgrade Guggenheim Buy → Neutral
Apr-25-19Upgrade Liberum Hold → Buy
Apr-25-19Upgrade Guggenheim Neutral → Buy
Apr-10-19Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-02-19Downgrade JP Morgan Neutral → Underweight
Dec-11-18Resumed Jefferies Buy
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Underperform → Buy
May-29-18Downgrade HSBC Securities Buy → Hold
May-25-18Upgrade Credit Suisse Underperform → Neutral
Jan-25-18Reiterated Leerink Partners Outperform $93 → $100
Dec-06-17Downgrade BofA/Merrill Neutral → Underperform
Jul-26-17Upgrade Morgan Stanley Underweight → Overweight
Jul-05-17Downgrade Credit Suisse Neutral → Underperform
Mar-09-17Initiated Liberum Buy
Mar-08-17Upgrade Societe Generale Hold → Buy
Mar-07-17Downgrade Exane BNP Paribas Neutral → Underperform
Jan-11-17Downgrade Credit Suisse Outperform → Neutral
Nov-10-16Upgrade Argus Hold → Buy
Oct-10-16Reiterated Chardan Capital Markets Buy $95 → $92
Feb-26-20 06:21AM  Dana-Farber teams up with investment firm to develop cancer drugs American City Business Journals
Feb-24-20 06:13AM  Boston-based startup Invetx joins animal biopharma stampede American City Business Journals -6.90%
Feb-21-20 10:03AM  Pharma Stock Roundup: AZN Reports Q4 Results, NVS, PFE Drugs Get EU Approval Zacks
Feb-20-20 09:00AM  Biogen Stock Recently Broke Out On A Patent Win Should You Buy Shares? Investor's Business Daily
Feb-13-20 10:24AM  Incyte (INCY) Q4 Earnings Top Estimates on Solid Jakafi Sales Zacks
Feb-12-20 12:34PM  Coronavirus outbreak begins to disrupt booming China drug trials Reuters
10:30AM  Buy AbbVie for its Growth Prospects, Yield and Low Valuation
09:18AM  The Daily Biotech Pulse: J&J Intensifies Efforts On COVID-19 Cure, Adamas Reports Positive, Long-Term Gocovri Data Benzinga
Feb-11-20 09:04AM  Incyte's (INCY) Capmatinib NDA Gets Priority Review From FDA Zacks
07:23AM  The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology Benzinga
Feb-10-20 09:18AM  Regeneron Reports Positive Eylea Data From Late-Stage Study Zacks
Feb-07-20 10:49AM  Ligand (LGND) Q4 Earnings & Revenues Top Estimates, Stock Up Zacks
09:44AM  Incyte (INCY) to Report Q4 Earnings: What's in the Cards? Zacks
09:25AM  Alnylam's (ALNY) Q4 Earnings Miss Estimates, Sales Beat Zacks
Feb-06-20 10:40AM  Regeneron's (REGN) Q4 Earnings & Sales Surpass Estimates Zacks
Feb-04-20 02:32PM  Eaton Vance Exits Celgene, Trims Amgen Position
12:27PM  A Pick and Shovel Strategy to Avoid Competition and Speculation
11:50AM  Teva's Two Pivotal Studies on Ajovy in Japan Meet Goal Zacks
10:22AM  Analysts Forecast Huge Upsides for Aimmune, Biohaven
Feb-03-20 10:09AM  Is a Disappointment in Store for Glaxo's (GSK) Q4 Earnings? Zacks
08:45AM  The Zacks Analyst Blog Highlights: Microsoft, Facebook, Novartis, Tesla and Raytheon Zacks
Jan-31-20 01:45PM  Top Stock Analyst Reports for Microsoft, Facebook & Novartis Zacks
10:32AM  Pharma Stock Roundup: LLY, PFE Q4 Results, JNJ's Coronavirus Vaccine Initiative Zacks
Jan-30-20 10:20AM  Biogen touts resilience but gives little guidance on Alzheimer's drug American City Business Journals
09:32AM  Biogen Stock Gets a Lift From Strong Earnings Report
07:19AM  Roche (RHHBY) 2019 Sales Solid on Robust Show by New Drugs Zacks
Jan-29-20 04:07PM  Novartis Edges Higher Into Buy Zone Even As Generic Drugs Struggle Investor's Business Daily
03:02PM  Rockville biotech opens new HQ as it goes on hiring spree American City Business Journals
11:11AM  Incyte's Phase III Atopic Dermatitis Study Meets Primary Goal Zacks
10:09AM  Novartis (NVS) Earnings and Revenues Miss Estimates in Q4 Zacks
09:05AM  Novartis Stock Is Rising as Earnings Inch Past Forecasts
08:30AM  The Daily Biotech Pulse: Novartis Earnings, Hepion's NASH Candidate Beats Rival Drugs, Annovis Bio To Debut Benzinga
03:40AM  Novartis says taxes hit fourth-quarter profit, but sees growth in 2020 MarketWatch
03:36AM  Novartis sees no coronavirus disruption amid China growth Reuters
03:00AM  Novartis sales rise 9% as new medicines provide a boost Financial Times
01:34AM  Novartis predicts rising sales and minimal disruption from coronavirus Reuters
Jan-28-20 10:03PM  Novartis/Big Pharma: dosing up Financial Times
10:27AM  Why Earnings Season Could Be Great for Novartis (NVS) Zacks
02:59AM  Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 (Revised) Zacks
Jan-27-20 08:16AM  Lilly (LLY) to Report Q4 Earnings: What's in the Cards? Zacks
06:05AM  Quench Bio launches with $50M to treat 'missing link' to inflammatory disease American City Business Journals
Jan-26-20 12:00AM  Why big pharma sees a remedy in data and AI Financial Times
Jan-24-20 01:50PM  New partnership aims to ease surging generic drug costs by making its own Yahoo Finance
09:54AM  Pharma Stock Roundup: J&J's Mixed Q4, Roche & Novartis' New Drugs Approval in EU Zacks
Jan-23-20 10:42AM  Jazz (JAZZ) Submits NDA for Xyrem Follow-On Candidate JZP-258 Zacks
08:51AM  Roche's Risdiplam Meets Primary Endpoint in Infants Study Zacks
08:13AM  Primary Drivers of the Chinese Economy Investopedia
Jan-22-20 02:28PM  Health stocks reverse coronavirus gains as one analyst says the market is overreacting Yahoo Finance
Jan-21-20 06:21PM  Novartis (NVS) Gets Approval for MS Drug Mayzent in Europe Zacks
09:26AM  Puma Biotech's (PBYI) Breast Cancer Drug Nerlynx Aids Growth Zacks
08:41AM  Jazz's (JAZZ) New Sleep Drug Sunosi Gets Approval in Europe Zacks
Jan-20-20 09:45AM  Is Novartis AG (NVS) A Suitable Pick for Value Investors? Zacks
Jan-17-20 08:19AM  Will J&J (JNJ) Roll Out Pharma Q4 Earnings With a Beat? Zacks
08:11AM  Pharma Stock Roundup: LLY Dermira Buyout Offer, Pipeline & Regulatory Updates Zacks
Jan-15-20 11:00PM  Gene therapies test Europes willingness to pay Financial Times
Jan-13-20 01:04PM  Novartis to speed access to $10 billion heart drug via NHS deal Reuters
10:17AM  Alnylam Provides Preliminary Q4 Sales for Onpattro & Givlaari Zacks
09:15AM  Novartis, U.K. National Health Service Partner for Trial of Cholesterol-Drug Candidate
01:02AM  UKs NHS teams with Novartis to launch heart attack drug trial Financial Times
Jan-10-20 05:00PM  Regeneron's Phase II Candidate Promising in Primary Analysis Zacks
11:51AM  3 Biotech Stocks to Bank on for Buyouts in 2020 InvestorPlace
10:21AM  The Zacks Analyst Blog Highlights: Novartis, McDonald's, Bristol-Myers Squibb, CME and UBS Zacks
Jan-09-20 02:43PM  Top Analyst Reports for Novartis, McDonald's & Bristol-Myers Squibb Zacks
Jan-08-20 05:53PM  Among Top 5 Pharma Companies, Pfizer Was the Worst Performer in 2019
07:00AM  Cambridge startup bringing AI to drug development raises $60M American City Business Journals
Jan-07-20 07:26AM  Why Bank of America expects the hot European pharmaceuticals sector to stumble and its not a fear of U.S. drug prices MarketWatch
Jan-06-20 01:52PM  New antibiotics struggle to generate sales, pharma companies hurt Yahoo Finance Video
Jan-03-20 11:48AM  Novartis, Merck and Allergan join those raising U.S. drug prices for 2020 Reuters
10:01AM  Incyte's (INCY) Itacitinib Fails in Late-Stage GVHD Study Zacks
09:19AM  Glaxo (GSK) Shares Continue to Witness Upside: Here's Why Zacks
Jan-02-20 04:42PM  Global Blood (GBT) Shares Double in a Year, Focus on Oxbryta Zacks
11:53AM  Novo Nordisk: A Rare Case of Pharma With Balanced Risk and Reward
Dec-31-19 08:45AM  3 Biotech Stocks Likely to Maintain Solid Momentum in 2020 Zacks
Dec-29-19 09:40PM  Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus Benzinga
Dec-27-19 10:53AM  ROSEN, NATIONAL TRIAL LAWYERS, Continues to Investigate Securities Claims Against Novartis AG NVS GlobeNewswire
Dec-26-19 11:53AM  Novartis AG (NVS) vs. Top 20 Hedge Fund Stocks in 2019 Insider Monkey
10:38AM  Epizyme (EPZM) Shares Soar on Lead Candidate's Progress Zacks
09:13AM  Incyte (INCY) Surges 44% YTD on Jakafi's Strong Performance Zacks
Dec-24-19 12:15PM  Biotech Leading in Q4: Best ETFs & Stocks Zacks
10:12AM  Allergan (AGN) Gets FDA Approval for Migraine Drug Ubrelvy Zacks
Dec-23-19 04:12PM  Pharma M&A Deals Likely To Be Smaller in 2020
Dec-21-19 08:00AM  Biogen Announced a Big Stock Buyback. It May Not Be a Great Use of Cash.
Dec-20-19 09:22AM  Pharma Stock Roundup: Lilly's Upbeat 2020 Outlook, FDA Nod for PFE & MRK's Drugs Zacks
06:03AM  Novartis wins Medicaid approval for new sickle cell drug in key U.S. states Reuters
Dec-19-19 05:51PM  4 More Biotechs With Blockbuster Potential
05:20PM  Fresh off first sickle cell drug approval, Global Blood strikes new deals American City Business Journals
10:01AM  AbbVie's JAK Inhibitor Rinvoq Receives Approval for RA in EU Zacks
07:52AM  The Daily Biotech Pulse: Seattle Genetics' Bladder Cancer Drug Gets FDA Nod, Paratek Wins Contract For Antibiotic Benzinga
06:49AM  Novartis plans to give away world's costliest therapy to some patients Reuters
Dec-17-19 10:27AM  Novartis' Asthma Candidate Fails in LUSTER Phase III Studies Zacks
Dec-16-19 05:13PM  Why this company ponied up $99M for a mid-Peninsula building American City Business Journals
04:08PM  This Biotech Just Gave Up A Breakout Why An Analyst Is Still Bullish Investor's Business Daily
01:43PM  Amarins fish-oil pill now available to millions more patients. But its still no Lipitor MarketWatch
12:01PM  Regeneron Stock Is Downgraded. Analyst Cites Tough Competition From a Novartis Drug.
07:37AM  Novartis Gets Positive CHMP Opinion for Wet AMD Drug Beovu Zacks
Dec-15-19 07:06PM  Theres more upside for biotech even after 24% gains in two months MarketWatch
Dec-13-19 04:50PM  European Dividend Aristocrats: 41 Top-Flight International Dividend Stocks Kiplinger
02:42PM  FDA approves Sarepta's muscular dystrophy drug Yahoo Finance Video
12:19PM  Biotech Stocks Burn A Hole In Big Pharma's Pocket; Look For More Mergers In 2020 Investor's Business Daily
10:29AM  Biotech Stocks Are Poised to Rise in 2020, Analyst Says. Here Is His Top Pick.
Novartis AG, together with its subsidiaries, researches, develops, manufactures, and markets healthcare products worldwide. The company's Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, cardiovascular, renal and metabolism, and established medicines. The company's Sandoz segment develops, manufactures, and markets active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives to third parties; manufactures and supplies active pharmaceutical ingredients and intermediates, such as antibiotics; manufactures and markets protein- or other biotechnology-based products, including biosimilars and provides biotechnology manufacturing services to other companies. Novartis AG has collaboration agreements with Amgen; University of California, Berkeley; Bristol-Myers Squibb; IBM Watson Health; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; Pear Therapeutics; and Pfizer. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerNov 12Buy12.00250,0003,000,0003,543,067Nov 12 04:15 PM
Novartis Bioventures Ltd10% OwnerMay 28Buy14.00168,6302,360,8201,769,641May 30 09:27 PM
Novartis Bioventures Ltd10% OwnerApr 26Sale1.03138,704142,8654,049,804Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 25Sale1.03563,096579,9894,188,508Apr 29 05:23 PM
Novartis Bioventures Ltd10% OwnerApr 24Sale1.0316,40316,8954,751,604Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 23Sale1.0327,55428,3814,768,007Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 22Sale0.977,1006,8874,795,561Apr 24 07:03 PM
Novartis Bioventures Ltd10% OwnerApr 15Sale0.9928,79428,5064,802,661Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 12Sale1.0430,90832,1444,831,455Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 11Sale1.0857,43862,0334,862,363Apr 15 09:26 PM
Novartis Bioventures Ltd10% OwnerApr 10Sale1.09140,230152,8514,919,801Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 09Sale1.0132,99133,3215,060,031Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 08Sale1.0227,52528,0765,093,022Apr 10 06:26 PM
Novartis Bioventures Ltd10% OwnerApr 05Sale1.0224,66125,1545,120,547Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 04Sale1.0147,90048,3795,145,208Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 03Sale0.9658,03355,7125,193,108Apr 05 05:14 PM
Novartis Bioventures Ltd10% OwnerApr 02Sale0.9751,75450,2015,251,141Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale1.9020,61039,1592,079,394Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerApr 01Sale0.95116,909111,0645,302,895Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale1.85106,540197,0992,100,004Apr 02 08:23 PM
Novartis Bioventures Ltd10% OwnerMar 29Sale0.9163,10057,4215,419,804Apr 02 08:09 PM
Novartis Bioventures Ltd10% OwnerMar 28Sale0.9488,83583,5055,482,904Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 27Sale0.9950,74950,2425,571,739Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 26Sale1.01177,762179,5405,622,488Mar 28 05:16 PM
Novartis Bioventures Ltd10% OwnerMar 15Sale1.9243,80084,0962,206,544Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 14Sale1.8813,80025,9442,250,344Mar 15 05:25 PM
Novartis Bioventures Ltd10% OwnerMar 13Sale2.12132,738281,4052,264,144Mar 15 05:25 PM